摘要
目的探讨利培酮对精神分裂症患者各项代谢指标的影响效应及其相关因素。方法累积符合入组标准的人院精神分裂症患者共56例，予以利培酮治疗16周，于治疗前后测腰围、血压、血糖、血脂等指标，与36名健康者做对照，并分析患者组发生代谢综合征（Metabolicsyndrome，MS）及各项代谢指标异常的危险因素。结果患者组MS发生率为12．50％，显著高于对照组的0％（P=0．026）；患者组16周末腰围、甘油三酯、高密度脂蛋白、餐后2h血糖的变化值[分别为：男（4．15±3．14）cm；女（4．41±2．86）cm，（0．26±0．51）mmol／L，（-0．09±0．19）mmol／L，（0．49±．84）mmol／L]均大于对照组[分别为男（0．76±1．09）cm；女（0．64±0．81）cm，（0．04±0．15）mmo]／L，（-0．01±0．12）mmol／L，（0．04±0．35）mmol／L]，差异有显著性（P〈0．05）；Logistic回归分析显示，发生MS及腰围、甘油三酯、餐后2h血糖异常的危险因素分别为糖尿病家史（OR20．34，95％C11．97～210）及年龄（OR1．19，95％C11．03～1．38）、基线腰围（OR1．26，95％C11．04～1．52）及肥胖家史（OR4．27，95％C11．21～15．1）、基线甘油三酯（0R73．88，95％C13．41～16．01）及基线收缩压（OR1．16，95％C11．00—1．33）、基线腰围（OR1．41，95％C11．08～1．84）及年龄（OR1．53，95％C11．02～1．31）。结论利培酮可引发腹型肥胖、糖脂代谢紊乱乃至MS；对年龄大、有糖尿病家史以及体态较胖的患者应慎用利培酮。
Objective To explore the affection and related factors of risperidone on the metabolic indexes in schizophrenia patients. Methods 56 cases hospitalized sehizophrenia patients were treated with risperidone for 16 weeks. Waistline, blood glucose and blood lipid, blood pressure and other indicators were observed before and after treatment, risk factors that caused metabolic syndrome （ MS ） and abnormal indexes were analyzed, and 36 healthy persons as control group. Results The rate of MS in patient group was obviously higher tha, dlat in control group （ 12.50% vs 0%, P = 0.026 ）. Waistline, triglyceride （ TG）, high density lipoprotein （ HDL-C ）, and 2 hours postprandial blood glucose （2hPG） in patient group （ （4.15 ± 3.14）cm in man and （4.41 ± 2.86）cm in woman, （0.26 ±0.51 ） retool/L, （ -0.09 ±0.19） mmol/L, （0.49 ±0.84） mmol/L） increased compared with that in con- trol group （ （ 0.76 ± 1.09 ） cm in man and （ 0.64 ± 0.81 ） cm in woman, （ 0.04± 0.15 ） mmol/L, （ - 0.01 ± 0.12 ） retool/L, （0.04 ± 0.35 ） mmol/L） at the 16th weekend, and difference was significantly （P 〈 0.05 ） . Logistic re- gression analysis showed that the risk factors were family history of diabetes Odds Ratio （OR） 20.34 （95% CI 1. 97 -210） and age OR 1.19 （ 95 % CI 1.03 - 1.38 ） , the basis waistline OR 1.26 （95 % CI 1.04 N 1.52） and fam- ily history of obesity OR 4.27（95% CI 1.21 - 15.1 ） ,the basis TG OR 73.88 （95% CI 3.41 - 16.01 ） and the basis systolic pressure OR I. 16（95% CI 1.00 -1.33 ） , the basis waistline OR 1.41 （95% CI 1.08 - 1.84 ） and age OR 1.53 （95% CI 1.02 N 1.31 ） in developed MS,abnormal rate of waistline,TG,and 2hPG. Conclusion Risperidone can cause abdominal obesity, metabolic disorders of glucose and lipid even MS. So it shoud be used carefully for the patient who is old and has family history of diabetes and obesity posture.
出处
《中华行为医学与脑科学杂志》
CAS
CSCD
北大核心
2011年第12期1104-1106,共3页
Chinese Journal of Behavioral Medicine and Brain Science
关键词
利培酮
精神分裂症
代谢指标
代谢综合征
Risperidone
Schizophrenia
Metabolic indexes
Metabolic syndrome
